ISIS Pharmaceuticals, Inc. Stock Nasdaq
Equities
US4643301090
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 624M | Sales 2025 * | 766M | Capitalization | 6.07B |
---|---|---|---|---|---|
Net income 2024 * | -572M | Net income 2025 * | -504M | EV / Sales 2024 * | 9.54 x |
Net cash position 2024 * | 111M | Net Debt 2025 * | 218M | EV / Sales 2025 * | 8.2 x |
P/E ratio 2024 * |
-10.5
x | P/E ratio 2025 * |
-12.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.13% |
Latest transcript on ISIS Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 12-06-30 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 00-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 14-02-02 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Joan Herman
BRD | Director/Board Member | 70 | 19-06-09 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |